Development of the second-generation anti-HER2 Affibody molecule ABY-027 for radionuclide therapy added advantages of a more stable tumor-seeking domain, higher affinity to albumin, and site-specific conjugation of the radionuclide [17]. Here, ERBB2 is linked to neoplasm.